Investment Thesis
LivaNova demonstrates strong top-line growth (10.7% YoY) and excellent gross margins (67.3%), but faces critical fundamental concerns: operating cash flow of only $15.2M (4.2% of revenue) with nearly zero free cash flow ($926K) indicates severe cash generation problems. The catastrophic 483.6% EPS decline and anemic ROE/ROA metrics (1.8%/0.9%) suggest the company is not efficiently converting revenue into shareholder value, raising questions about earnings quality and operational efficiency.
Strengths
- Strong gross margin of 67.3% indicates competitive product positioning in medical device sector
- Revenue growth of 10.7% YoY demonstrates market acceptance and demand
- Solid balance sheet with $539.7M cash reserves and low leverage (0.24x debt/equity ratio)
Risks
- Catastrophic diluted EPS decline of 483.6% YoY signals severe profitability deterioration or significant one-time charges
- Critical cash flow weakness: operating cash flow only $15.2M (4.2% OCF margin) with free cash flow of $926K is unsustainable
- Extremely poor returns on equity (1.8%) and assets (0.9%) indicate capital inefficiency and operational dysfunction
Key Metrics to Watch
- Operating cash flow trends and OCF margin recovery to healthy 15-20% levels
- Free cash flow sustainability and ability to fund operations without burning reserves
- EPS stabilization and ROE improvement trajectory
Financial Metrics
Revenue
362.3M
Net Income
22.3M
EPS (Diluted)
$0.40
Free Cash Flow
926.0K
Total Assets
2.5B
Cash
539.7M
Profitability Ratios
Gross Margin
67.3%
Operating Margin
11.4%
Net Margin
6.2%
ROE
1.8%
ROA
0.9%
FCF Margin
0.3%
Balance Sheet & Liquidity
Current Ratio
1.33x
Quick Ratio
1.11x
Debt/Equity
0.24x
Debt/Assets
51.9%
Interest Coverage
2.61x
Long-term Debt
285.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T11:01:19.397470 |
Data as of: 2026-03-31 |
Powered by Claude AI